| Zhang, Helong |
TORCHLIGHT, NCT04085276: Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment |
|
|
| Active, not recruiting | 3 | 531 | RoW | JS001, Nab-Paclitaxel, Placebo | Shanghai Junshi Bioscience Co., Ltd. | Triple-Negative Breast Cancer | 12/24 | 12/25 | | |
NCT04990063: Adoptive TKC Transfer Combined With Chemotherapy for Advanced Non-small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 1 | 20 | RoW | Chemotherapy, Adoptive TKC transfer therapy | suhaichuan, Shanghai Biomed-union Biotechnology Co., Ltd. | Advanced Non-small Cell Lung Cancer, Chemotherapy | 08/22 | 11/23 | | |
| Wu, Tao |
NCT04385550: A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma |
|
|
| Not yet recruiting | 3 | 528 | RoW | Anlotinib hydrochloride capsule, AK105 injection, Paclitaxel injection, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma | 10/23 | 12/23 | | |
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer |
|
|
| Active, not recruiting | 3 | 866 | Europe, Japan, US, RoW | Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219 | Eli Lilly and Company, Eli Lilly and Company | Breast Neoplasms, Neoplasm Metastasis | 06/24 | 08/27 | | |
NCT06419621: PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic Triple-negative Breast Cancer |
|
|
| Recruiting | 3 | 360 | RoW | PM8002, Nab-Paclitaxel, Placebo | Biotheus Inc. | Triple Negative Breast Cancer(TNBC) | 07/27 | 07/28 | | |
TQ05105-III-01, NCT06682169: Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease |
|
|
| Recruiting | 3 | 182 | RoW | Rovadicitinib, Imatinib, Methotrexate, Mycophenolate mofetil, Rituximab | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Graft-versus-host Disease | 10/29 | 12/30 | | |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
| Active, not recruiting | 2/3 | 580 | RoW | Apatinib 250mg, Camrelizumab, S-1, Oxaliplatin, Apatinib 500mg | Ruijin Hospital | Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma | 12/24 | 08/25 | | |
NCT06300320: A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease |
|
|
| Recruiting | 2 | 40 | RoW | TQ05105 tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Graft Versus Host Disease | 10/25 | 04/26 | | |
NCT05221658: A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCC |
|
|
| Recruiting | 2 | 60 | RoW | HLX07+HLX10+ Cisplatin+5-FU, HLX07 | Shanghai Henlius Biotech | ESCC or Esophageal Adenosquamous Carcinoma | 06/24 | 08/25 | | |
TQB2102-II-02, NCT06452706: The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer |
|
|
| Recruiting | 2 | 42 | RoW | TQB2102 for injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Breast Cancer | 06/26 | 06/28 | | |
NCT05033132: A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer |
|
|
| Withdrawn | 2 | 177 | RoW | Balstilimab, Balstilimab + Zalifrelimab | Agenus Inc., Betta Pharmaceuticals Co., Ltd. | Cervical Cancer | 12/24 | 12/24 | | |
| Recruiting | 1/2 | 380 | RoW | PM8002 | Biotheus Inc. | Malignant Neoplasm | 11/25 | 11/25 | | |
| Recruiting | 1 | 92 | RoW | TQB2223 injection+ Penpulimab Injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Cancer | 01/25 | 01/26 | | |
NCT03377829: A Multicenter Trial of PLA vs. Surgery for Treating PTMC |
|
|
| Recruiting | N/A | 200 | Europe, RoW | PLA, Thyroid Surgery | WeiWei Zhan | Thyroid Cancer, Treatment Related Cancer | 08/21 | 12/22 | | |
HEROIC, NCT06551220: Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer with Different HER2 Expression Patterns |
|
|
| Recruiting | N/A | 800 | RoW | Trastuzumab Deruxtecan | Sun Yat-sen University | Metastatic Breast Cancer | 01/25 | 01/25 | | |
NCT05872360: To Investigate Effects of Amway Bundle Combination of Products on Osteoarthritis & Sarcopenia |
|
|
| Completed | N/A | 240 | RoW | Bundle Group 1 with Nutrilite Lifestyle, Bundle Group 2 without Nutrilite Lifestyle, Control Group 1, Control Group 2 with Nutrilite Lifestyle | Amway (China) R&D Center | Osteoarthritis, Sarcopenia | 02/24 | 02/24 | | |
| He, DongJie |
| Not yet recruiting | N/A | 60 | RoW | Endostar, S1 | Peking University Third Hospital, Mianyang Central Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing Cancer Hospital, Peking University International Hospital, China-Japan Friendship Hospital, The fifth medical center of PLA general hospital, Second Hospital of Shanxi Medical University, Hiser Medical Center of Qingdao, Guangxi Ruikang Hospital, GEM flower hospital of Liaohe oil field, Tang-Du Hospital, Third Affiliated Hospital of Guizhou Medical University, Liuzhou Worker's Hospital, The Affiliated Hospital of Xuzhou Medical University, Dalian municipal central hospital affiliated of dalian medical university | Radiotherapy Side Effect | 01/22 | 01/23 | | |
| Du, Xilin |
NCT05862337: Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence. |
|
|
| Recruiting | 3 | 480 | RoW | Anlotinib hydrochloride capsules, Penpulimab injection, Anlotinib hydrochloride capsules -matching placebo, Penpulimab injection -matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Hepatocellular Carcinoma | 08/24 | 12/26 | | |
TIPS, NCT06196723: Transjugular Intrahepatic Portosystemic Shunts Improve Survival in Patients With Cirrhosis and Recurrent Ascites |
|
|
| Completed | N/A | 462 | RoW | transjugular intrahepatic portal shunt | Tang-Du Hospital | Refractory Ascites | 02/24 | 02/24 | | |
